Hashimoto's Thyroiditis: Four Stages of Disease Evolution

Introduction

Hashimoto's thyroiditis (chronic autoimmune thyroiditis) is the most common cause of hypothyroidism in iodine-sufficient regions. In everyday practice it is often framed as a single-point diagnosis: elevated thyroid peroxidase antibodies (anti-TPO) plus an abnormal thyroid-stimulating hormone (TSH) equal a prescription for levothyroxine. That approach ignores the underlying biology: Hashimoto's is a slow, multi-year process that progresses through four sequential stages, with 10–20 years sometimes separating stage 1 from stage 3.

Recognizing the stage changes everything: surveillance interval, lab cadence, the moment to start replacement therapy, and prognosis. Starting levothyroxine in the euthyroid stage — when thyroid function is intact — is not prophylaxis; it is blind therapy that does not halt the autoimmune process. In stages 1–2 I observe and support; in stages 3–4 I prescribe replacement — the staging is a clinical model not used in ATA guidelines.

This article maps the four stages of Hashimoto's, the markers that define each, the timing of progression, the risk factors that accelerate transition, and the stage-specific protocol.

🌀

Mechanism: the biology of staging

Hashimoto's is a T-cell-mediated autoimmune destruction of thyrocytes. The main actors are CD8+ cytotoxic lymphocytes (direct cell killing), Th1 cytokines (IFN-γ, TNF-α — sustaining the inflammatory loop), and anti-TPO and anti-Tg antibodies (markers, not the primary destroyers). The antibodies themselves do not lyse the gland — they tag the process driven by lymphocytes.

Laboratory staging hinges on three parameters:

▸TSH — rises with stage. It is the most sensitive marker of incipient hypothyroidism because the pituitary responds first to even a slight drop in free T4. ▸Free T4 (fT4) — drops only from stage 3 onward. In stages 1–2 fT4 remains normal thanks to compensatory thyrocyte hyperfunction. ▸Anti-TPO — peaks in stages 2–3. In stage 4 antibodies may decline because there is no remaining target tissue.

Adjuncts: thyroid ultrasound shows hypoechogenicity from stage 1 (histologically — lymphocytic infiltration), and fibrosis from stage 4. Gland volume follows a U-shape: normal (stage 1) → enlarged from lymphocytic infiltration (stages 2–3) → shrunken and atrophic (stage 4). The Zulewski thyroid symptom score becomes sensitive to subclinical hypothyroidism from stage 2.

🌀

Stage 1 — euthyroid

The longest and most silent stage. Biochemical profile: anti-TPO↑, TSH and fT4 normal. Clinically asymptomatic. Duration 5–15 years, sometimes longer.

Autoimmune attack is already active, but follicles compensate the cell loss by raising the functional output of the surviving tissue. Histologically — focal lymphocytic infiltration with germinal centers in the stroma. Biochemically — full compensation.

Population prevalence of anti-TPO carriage: 10–15% of women, 3–5% of men. Most of these people never reach stage 3. Vanderpump and colleagues (PMID 7641412) showed in the 20-year Whickham survey that asymptomatic women with isolated anti-TPO↑ had a 2.1% annual risk of progressing to overt hypothyroidism; with antibodies and TSH above 6 mU/L the risk rose to 4.3% per year.

Stage 1 strategy: annual surveillance — TSH + anti-TPO. Selenium 200 µg/day if deficiency is confirmed or antibody titers rise quickly (in a meta-analysis of RCTs it lowered anti-TPO after 3 months). Vitamin D — target > 30 ng/mL (75 nmol/L). Levothyroxine at this stage is unjustified and does not prevent progression.

🌀

Stage 2 — subclinical

Biochemical profile: TSH 4–10 mIU/L, fT4 normal. First soft symptoms appear: fatigue, weight gain, slowed metabolism, dry skin, brittle hair, constipation. The symptoms are nonspecific and easy to attribute to age, stress, or poor sleep.

This is the critical decision-making stage. Vanderpump (PMID 7641412) showed that women with anti-TPO↑ and TSH above 6 mU/L progress to overt disease at 4.3% per year. Up to 5% per year transition to stage 3.

When to start levothyroxine in stage 2? The ATA Guideline recommends considering initiation when:

▸TSH > 10 mIU/L — clear indication even with normal fT4. ▸TSH 4.5–10 mIU/L + hypothyroid symptoms — individualized decision; trial therapy for 3–6 months and reassess symptoms. ▸Pregnancy or pregnancy planning — a reason to discuss levothyroxine before conception; on levothyroxine — the lower half of the trimester-specific range, or below 2.5 mIU/L if none (ATA 2017). ▸Infertility or recurrent miscarriage — subclinical hypothyroidism is a proven risk factor. ▸Dyslipidemia unresponsive to diet and statins — subclinical hypothyroidism elevates LDL and total cholesterol.

Patients without these criteria in stage 2 should be observed every 6 months with immunomodulatory support. See hypothyroidism and natural desiccated thyroid (NDT) for context on replacement options.

🌀

Stage 3 — overt

Biochemical profile: TSH > 10 mIU/L, fT4 ↓. The full clinical picture of hypothyroidism: bradycardia (heart rate < 60), dry skin, facial puffiness (myxedema), hair loss (including the lateral third of the eyebrows — Hertoghe sign), depression, constipation, hypercholesterolemia (predominantly LDL), delayed deep tendon reflexes, cold intolerance, menstrual irregularity, decreased libido.

This is an unequivocal indication for replacement therapy. Levothyroxine 1.6–1.7 µg/kg body weight is the standard starting dose. With coronary artery disease, start at 12.5–25 µg/day and increase gradually guided by symptoms and TSH; over 60 a lower start is common — the physician decides.

Dosing principles:

▸Morning fasting, 30–60 minutes before breakfast — absorption is maximal on an empty stomach. Coffee, calcium, iron, and proton pump inhibitors decrease absorption; keep calcium and iron no closer than 4 hours to the tablet. ▸TSH check — 6–8 weeks after initiation or dose change. Earlier checks are uninformative because T4 has a 7-day half-life and steady state requires 5–6 half-lives. ▸Target TSH — 0.5–2.5 mIU/L in patients < 60, 1.0–4.0 mIU/L in patients > 60. ▸fT3 and T4 → T3 conversion — in 5–10% of people on levothyroxine, complaints persist despite a normal TSH; one possible cause is a lack of T3. See T4 to T3 conversion, deiodinases, and functional hypothyroidism for the mechanism and the NDT/liothyronine alternatives.

Low-dose naltrexone (LDN) is a separate immunomodulatory option in combined Hashimoto's management at stages 2–3; see LDN in Hashimoto's.

🌀

Stage 4 — atrophic

The terminal phase. The thyroid gland is shrunken, with marked stromal fibrosis, loss of follicles, and replacement of functional tissue by connective tissue. Ultrasound criteria for atrophy: volume < 8 mL in men, < 6 mL in women. Echo-structure is hypoechoic, heterogeneous, with hyperechoic fibrotic foci.

Labs: TSH high or normalized under adequate replacement, fT4 low without replacement. Anti-TPO may begin to decline — this is not remission but the absence of target tissue for autoimmune attack. If anti-TPO was previously 800 IU/mL and is now 50–100 IU/mL, this marks atrophy, not cure.

Therapy is lifelong. TSH monitoring once a year on a stable dose, more often during weight changes (> 5%), pregnancy, or addition of drugs that alter thyroid hormone absorption or metabolism (estrogens raise levothyroxine requirements; androgens lower them).

🌀

Common pitfalls

General practice consistently makes four kinds of errors:

▸Prescribing levothyroxine in stage 1 — based on isolated anti-TPO↑ with normal TSH and fT4. This is blind therapy that does not prevent progression and risks iatrogenic hyperthyroidism. ▸Ignoring stage 2 in young women — subclinical hypothyroidism (TSH 4.5–10 mIU/L) with anti-TPO↑ in a woman aged 25–35 planning pregnancy is a reason to discuss levothyroxine before conception, not just to observe. ▸Monotherapy with levothyroxine despite persistent symptoms — a normalized TSH is not the same as clinical compensation. In 5–10% of people on levothyroxine, complaints persist despite a normal TSH; one possible cause is a lack of T3. ▸High-dose iodine in established autoimmune thyroiditis — iodine > 500 µg/day in patients with autoimmune thyroiditis accelerates the autoimmune process via iodine-induced hypothyroidism (Wolff-Chaikoff effect). Target intake should not exceed 250 µg/day.

🌀

Full panel: what to measure, and when

Recommended laboratory panel for staging and monitoring:

▸TSH — baseline screen, reflex test. ▸Free T4 (fT4) — required when TSH > 4 or < 0.4. ▸Free T3 (fT3) — from stage 3 and whenever impaired conversion is suspected. ▸Anti-TPO — to confirm autoimmune etiology. ▸Anti-Tg — in a subset of patients anti-TPO is negative while anti-Tg is positive; they do not duplicate one another. ▸Reverse T3 (rT3) — in stress, undernutrition, severe comorbid illness. ▸Thyroid ultrasound — baseline (volume, echotexture, nodules), then annually. ▸Vitamin D, ferritin, selenium, zinc — cofactors without which thyroid hormone synthesis and conversion are impaired.

Supplements with human data:

▸Selenium 200 µg/day — lowered anti-TPO after 3 months (meta-analysis of RCTs). ▸Vitamin D — target 30–60 ng/mL (75–150 nmol/L); correct any deficiency. ▸Gluten-free diet when celiac disease is co-present — 5% of patients with autoimmune thyroiditis also have celiac; treating it lowers anti-TPO. ▸Stress control and 7–8 hours of sleep — cortisol and catecholamines modulate Treg activity. ▸Iodine intake ≤ 250 µg/day.

🌀

Monitoring cadence

Lab follow-up by stage:

▸Stage 1 (euthyroid) — TSH + anti-TPO once a year. Ultrasound once a year. ▸Stage 2 (subclinical) — TSH + fT4 every 6 months. After starting levothyroxine, recheck at 6–8 weeks. ▸Stage 3 (overt) on levothyroxine initiation — TSH every 6–8 weeks until stable, then every 3 months for the first year, then every 6 months. ▸Stages 3–4 on a stable dose — TSH once a year and whenever weight or comorbid status changes. ▸Pregnancy — TSH every 4 weeks until mid-pregnancy and at least once around week 30.

The Zulewski thyroid symptom score is a validated bedside tool for assessing clinical compensation. I use it at baseline and every 3 months in patients on replacement. A normalized TSH alongside a high symptom score is a signal to check fT3 and discuss NDT or T4 + liothyronine combination therapy.

🌀

Caution

A few non-negotiable contexts:

▸Pregnancy — the TSH target is different: on levothyroxine — the lower half of the trimester-specific range, or below 2.5 mIU/L if none (ATA 2017). Co-manage with obstetrics. ▸Elderly patients > 75 years — target TSH is higher (up to 4–6 mIU/L); aggressive suppression < 1 carries atrial fibrillation and osteoporosis risk. ▸Coronary artery disease — initiate levothyroxine at 12.5–25 µg/day with slow titration and ECG and anginal monitoring. ▸Pregnancy + autoimmune thyroiditis + subclinical hypothyroidism — active indication for therapy regardless of stage. ▸Distinguish from de Quervain thyroiditis — subacute thyroiditis shows a similar ultrasound picture, but the clinical course is acute, the gland is painful, ESR is elevated, and radioiodine uptake is suppressed. The therapy is fundamentally different. ▸Drug interactions with levothyroxine — calcium, iron, omeprazole, estrogens, antiepileptics affect absorption and metabolism. After starting a new drug, recheck TSH in 6–8 weeks.

🌀

Bottom line

You treat the stage, not the diagnosis. In stages 1–2 I observe and support; in stages 3–4 I prescribe replacement with a fit-for-patient regimen (levothyroxine, NDT, or combination). The staging is a clinical model not used in ATA guidelines. Prescribing levothyroxine in stage 1 without functional impairment is blind therapy that fails to prevent progression and creates iatrogenic risk.

Hashimoto's is a process, not a point. Knowing the stage changes the strategy, the prognosis, and the patient's quality of life.

🌀

About the author

I am Dr. Vladimir Pereligyn, endocrinologist and researcher. I specialize in endocrine, metabolic, and autoimmune protocols with a holistic approach and individualized lab diagnostics. Book a consultation — universum.earth/consultation. Daily clinical breakdowns — @md_pereligyn_thyroid.

🌀

Sources

▸Vanderpump MPJ, et al. The incidence of thyroid disorders in the community: Whickham 20-year follow-up. Clin Endocrinol 1995. (PMID 7641412) ▸Toulis KA, et al. Selenium supplementation in autoimmune thyroiditis: meta-analysis of RCTs. Thyroid 2010. (PMID 20883174) ▸Wiersinga WM, et al. 2012 ETA Guidelines: combination treatment with LT4 + LT3 in primary hypothyroidism. Eur Thyroid J 2012. (PMID 24782999)

This article is for informational purposes only and does not replace a medical consultation. Before starting any supplements, changing medication, or undergoing diagnostic procedures, discuss the plan with your physician.